IRAK2抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Jurkat and K562 cell lysates, Primary antibody: P07396(IRAK2 Antibody) at dilution 1/1600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07396(IRAK2 Antibody) at dilution 1/125. (Original magnification: ×200)    

  
  

The IRAK2 (Interleukin-1 Receptor-Associated Kinase 2) antibody is a key tool for studying the IRAK2 protein, a critical mediator in innate immune signaling pathways. IRAK2 belongs to the IRAK family of serine/threonine kinases, which includes IRAK1. IRAK3 (IRAK-M), and IRAK4. These proteins are central to Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling, driving inflammatory responses by activating NF-κB and MAPK pathways. Unlike IRAK1. IRAK2 lacks kinase activity in some splice variants but acts as a scaffold protein, facilitating downstream signal transduction. It plays dual roles in immune regulation, promoting pro-inflammatory cytokine production while also contributing to negative feedback mechanisms to prevent excessive inflammation.

IRAK2 antibodies are widely used in research to detect IRAK2 expression, localization, and post-translational modifications (e.g., phosphorylation) via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Dysregulation of IRAK2 is implicated in autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancers, making it a potential therapeutic target. Studies using IRAK2 antibodies have revealed its role in metabolic disorders and sepsis, highlighting its broad physiological impact. Researchers also utilize these antibodies to explore IRAK2’s interaction with adaptor proteins like MyD88 and TRAF6. aiding the development of inhibitors for inflammatory diseases. Commercial IRAK2 antibodies are typically validated for specificity across human, mouse, and rat models.